Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GANX Gain Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: GANX
Price (delayed)
$1.94
Market cap
$53.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.89
Enterprise value
$44.17M
Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new
Highlights
The EPS has grown by 48% YoY and by 19% from the previous quarter
Gain Therapeutics's debt has decreased by 36% YoY and by 15% QoQ
GANX's revenue has plunged by 100% YoY
Gain Therapeutics's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of GANX
Market
Valuations
Earnings
Shares outstanding
27.79M
Market cap
$53.91M
Enterprise value
$44.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
7.01
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$20.35M
Net income
-$20.41M
EBIT
-$19.87M
EBITDA
-$19.79M
Free cash flow
-$18.9M
Per share
Balance sheet
Liquidity
EPS
-$0.89
EPS diluted
-$0.89
Free cash flow per share
-$0.83
Book value per share
$0.28
Revenue per share
$0
TBVPS
$0.52
Total assets
$12.12M
Total liabilities
$4.78M
Debt
$653,015
Equity
$7.34M
Working capital
$7.69M
Debt to equity
0.09
Current ratio
2.97
Quick ratio
2.66
Net debt/EBITDA
0.49
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-135.5%
Return on equity
-222.6%
Return on invested capital
N/A
Return on capital employed
-242%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GANX stock price
How has the Gain Therapeutics stock price performed over time
Intraday
-4.2%
1 week
-5.83%
1 month
17.58%
1 year
-23.62%
YTD
-10.19%
QTD
1.57%
Financial performance
How have Gain Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.35M
Net income
-$20.41M
Gross margin
N/A
Net margin
N/A
GANX's revenue has plunged by 100% YoY
Gain Therapeutics's gross profit has shrunk by 100% YoY
GANX's operating income is up by 9% YoY and by 5% QoQ
The net income is up by 8% year-on-year and by 4.5% since the previous quarter
Price vs fundamentals
How does GANX's price correlate with its fundamentals
Growth
What is Gain Therapeutics's growth rate over time
Valuation
What is Gain Therapeutics stock price valuation
P/E
N/A
P/B
7.01
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 48% YoY and by 19% from the previous quarter
The stock's price to book (P/B) is 103% more than its 5-year quarterly average of 3.6 and 33% more than its last 4 quarters average of 5.5
GANX's equity is down by 42% year-on-year and by 18% since the previous quarter
GANX's revenue has plunged by 100% YoY
Efficiency
How efficient is Gain Therapeutics business performance
Gain Therapeutics's return on equity has decreased by 15% YoY and by 9% QoQ
GANX's return on assets is down by 10% year-on-year and by 6% since the previous quarter
Dividends
What is GANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GANX.
Financial health
How did Gain Therapeutics financials performed over time
GANX's total assets is 153% greater than its total liabilities
GANX's total assets is down by 35% year-on-year and by 16% since the previous quarter
GANX's quick ratio is down by 22% YoY
Gain Therapeutics's debt is 91% lower than its equity
GANX's equity is down by 42% year-on-year and by 18% since the previous quarter
Gain Therapeutics's debt has decreased by 36% YoY and by 15% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.